At the National Academy of Neuropsychology Conference in Los Angeles, Dr. Youssef Khattab, Research Coordinator at OHSU, presented new NAPS data titled “Quantifying cognitive change across one year in RBD: Initial follow-up of the NAPS Consortium study.

Better and faster science in synucleinopathies can bring us closer to neuroprotective clinical trials.

In a recent issue of Current Neurology and Neuroscience Reports, Drs. Lee Neilson and Miranda Lim, NAPS Investigators from Oregon Health Sciences University, review cutting-edge science in REM Sleep Behavior Disorder (RBD) and synucleinopathies.

Could we use wearable trackers to screen for RBD? 💭

Dr. Emmanuel During and colleagues reported a fascinating case in JAMA Neurology.

Dr. Albert “Gus” Davis joined experts in sleep, epilepsy, and circadian medicine for an engaging session exploring how these systems intertwine to influence neurological health at ANA2025.

Dr. Chengjie Xiong, leader of the NAPS Data & Statistical Management Core, shared groundbreaking findings at the International Parkinson and Movement Disorder Society Congress.

NAPS hosted the 3rd Annual Industry Roundtable concurrent with the Movement Disorders Society Congress in Honolulu, bringing together leaders from across academia and industry with one shared goal – preparing for neuroprotective treatment trials for synucleinopathies.

Earlier this year, president Joe Biden recognized Miranda Lim, M.D., Ph.D. (OHSU) with the Presidential Early Career Award for Scientists and Engineers (PECASE) – the nation’s highest honor for early-career researchers.

Dr. Lim is one of only 14 recipients from the U.S. Department of Veterans Affairs and among about 400 awardees nationwide.

At the 2025 World Sleep Congress in Singapore, our investigators highlighted the powerful intersections of sleep, epilepsy, and circadian health.

New research led by NAPS Co-Principal Investigator Dr. Ronald Postuma, sheds light on the earliest signs of synucleinopathies like Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy.

Dr. Lynn Marie Trotti has been named the new Director of the Emory Sleep Center, succeeding Dr. Nancy Collop, who retires after 15 years of transformative leadership.

We’re thrilled to share that Dr. Susan Criswell, Co-Leader of the NAPS Consortium’s Neuroimaging Core, has been named Chief Medical Officer for Clinical Research at Barrow Neurological Institute.

New research shows that REM sleep behavior disorder (RBD) takes a toll not only on people with Parkinson’s disease but also on their partners.

A recent study by NAPS Investigators Drs. Trotti and Bilwise from Emory University, following 323 adults over ~2.5 years, found that symptoms of idiopathic hypersomnia remain largely stable.

New research highlights the role of the gut in Parkinson’s disease subtypes.

Using metabolomics, scientists compared blood samples from Parkinson’s patients with and without REM sleep behavior disorder (RBD).

Emmanuel During, MD, an associate professor of neurology at the Icahn School of Medicine at Mount Sinai, discussed the external validation of an actigraphy-based classifier for diagnosing iRBD and its implications for scalable neurodegenerative screening.

Acting out in your sleep? New guidelines could help keep you safe.

A simple skin swab could detect Parkinson’s up to 7 years before symptoms appear.

A groundbreaking study published in JAMA Neurology, led by Dr. Lee Neilson, a NAPS investigator at Oregon Health Sciences University, explores the connection between hearing loss and Parkinson's disease (PD) risk in over 3 million US veterans.